Sign In
Buy VIR
$8.66
-0.240 (-2.70%)
At Close: Jul 31, 2026
FDA approves Vir Biotechnology antibody drug for emergencies
02:46pm, Monday, 31'st May 2021
George Scangos, President and CEO of Vir Biotechnology, joined Yahoo Finance's Julia LaRoche and Adam Shapiro to discuss the latest on the company's COVID-19 antibody treatment. Watch the 2021 Berkshi
The FDA authorized the third monoclonal antibody treatment. Here's why Vir and GSK say the U.S. still needs COVID-19 therapies
12:34pm, Thursday, 27'th May 2021
There are now three antibody-based treatments available in the U.S. to treat adults and teens with mild or moderate forms of COVID-19, though all require intravenous infusions and are not the kind of
Vir Biotechnology gains 10% after receiving EUA for its COVID-19 treatment
10:07am, Thursday, 27'th May 2021
Vir Biotechnology Inc (NASDAQ: VIR) shares jumped roughly 10% in after-hours trading on Wednesday as the company received emergency use authorisation for its COVID-19 drug from the U.S Food and Drug A
GlaxoSmithKline and Vir win FDA emergency authorization for COVID antibody treatment in adults and children
06:29am, Thursday, 27'th May 2021
GlaxoSmithKline plc and Vir Biotechnology Inc. said the U.S. Food and Drug Administration has granted emergency use authorization to its single-dose monoclonal antibody treatment sotrovimab in mild-to
– Treatment with sotrovimab resulted in an 85% reduction in the risk of hospitalization or death in high-risk adult outpatients compared to placebo, based on interim results from Phase 3 COMET-ICE
Glaxo (GSK)/ Vir Biotech's COVID-19 Antibody Gets CHMP Nod
01:32pm, Monday, 24'th May 2021
The CHMP issues a positive scientific opinion on Glaxo (GSK) and partner Vir Biotech's antibody candidate, sotrovimab (VIR-7831), for the treatment of adults and adolescents with COVID-19 infection.
– Opinion based on the EMA's Committee for Human Medicinal Products (CHMP) review of available data on sotrovimab (previously VIR-7831) for the early treatment of COVID-19 –
EMA Issues Positive Scientific Opinion on GSK and Vir Biotechnology's Sotrovimab For the Early Treatment of COVID-19
08:04am, Friday, 21'st May 2021
– Opinion based on the EMA's Committee for Human Medicinal Products (CHMP) review of available data on sotrovimab (previously VIR-7831) for the early treatment of COVID-19 –
– Rolling review will evaluate sotrovimab in adults and adolescents with COVID-19 who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19 –
Vir Biotechnology, Inc. (VIR) Reports Q1 Loss, Misses Revenue Estimates
08:17pm, Thursday, 06'th May 2021
Vir Biotechnology, Inc. (VIR) delivered earnings and revenue surprises of -473.91% and -98.84%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the sto
Vir Biotechnology: Not Nearly Enough
06:10pm, Wednesday, 21'st Apr 2021
VIR did well with the prophylaxis studies but failed to impress with the hospitalisation data. Upcoming EUA and EMA reviews may be catalytic.
Brii Biosciences, Vir Biotech, VBI Vaccines Start Combination Therapy Hepatitis B Study
08:50am, Wednesday, 21'st Apr 2021
Privately-held Brii Biosciences, Vir Biotechnology Inc (NASDAQ: VIR), and VBI Vaccines Inc (NASDAQ: VBIV) have dosed the first patient in a Phase 2 trial evaluating BRII-835 (VIR-2218) in c
Could Vir Biotechnology Be a Millionaire Maker Stock?
06:00am, Saturday, 17'th Apr 2021
Vir is developing treatments in billion-dollar markets.
Glaxo (GSK)/ Vir Biotech COVID-19 Antibody Under Review in EU
08:19am, Friday, 16'th Apr 2021
The EMA starts review of Glaxo (GSK) and partner Vir Biotech's antibody candidate, VIR-7831, for the treatment of adults and adolescents with COVID-19 infection.
Vir Biotechnology Announces New Research Demonstrating Novel Mechanisms by Which SARS-CoV-2 Enters Host Cells
08:30am, Thursday, 08'th Apr 2021
– Growing body of evidence suggests monoclonal antibodies that target a conserved epitope have the potential to be highly effective against SARS-CoV-2 and associated known mutations –
